Select publications

Boccardo F et al. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Proc SABCS 2003(Suppl 1);Abstract 3.

Castiglione-Gertsch M et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 2003;95(24):1833-46. Abstract

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Colleoni M et al. Randomized comparison of adjuvant tamoxifen (Tam) versus no hormonal treatment for premenopausal women with node-positive (N+), early stage breast cancer: First results of International Breast Cancer Study Group Trial 13-93. Proc ASCO 2004;Abstract 532.

Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract

Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapyinduced neutropenia. Semin Oncol 2003;30(4 Suppl 13):24-30. Abstract

Davidson NE et al. Chemohormonal therapy in premenopausal, node-positive, receptorpositive breast cancer: An Eastern Cooperative Oncology Group Phase III Intergroup trial (E5188,INT-0101). Proc ASCO 2003;Abstract 15.

Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (Anastrozole, Tamoxifen, Alone or in Combination) trial according to estrogen receptor and progesterone receptor status. Proc SABCS 2003;82(Suppl 1);Abstract 4.

George S et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44(10):1691-6. Abstract

Geyer CE Jr et al. Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of Adriamycin and cyclophosphamide (AC) followed by Taxol to that of AC followed by Taxol plus Herceptin in patients (Pts) with operable, nodepositive (N+), HER-2 overexpressing breast cancer (HER2+BC). Proc SABCS 2003;Abstract 23.

Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793-802. Abstract

Grigg A et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44(9):1503-8. Abstract

Kaufmann M et al; Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists’ Group. Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 2003;39(12):1711-7. Abstract

Perez EA et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22(18):3700-4. Abstract

Proceedings of the 8th International Conference on Primary Therapy of Early Breast Cancer. St. Gallen, Switzerland, 12-15 March 2003. Breast 2003;12(6):349-582. No abstract available

Ravdin PM et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-91. Abstract

Saphner T et al. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14(10):2738-46. Abstract

Siena S et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003;10(3):715-24. Abstract

Tan AR, Swain SM. Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol 2003;30(5 Suppl 16):54-64. Abstract

Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology 2002;63(Suppl 1):57-63. Abstract